MedPath

Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis

Conditions
Pancreatitis, Acute
Registration Number
NCT03364920
Lead Sponsor
Weiqin Li
Brief Summary

This is a retrospective study about serum Maresin-1 level in different severe acute pancreatitis patients. The investigators want to study the correlation between the level of serum Maresin-1 and the severity of SAP, of course the clinical outcomes. The investigators want to find some biomarkers and strategy target drugs of severe acute pancreatitis.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Clinical diagnosis of Severe Acute Pancreatitis
  • Biliary pancreatitis
  • 7 days of the onset
Exclusion Criteria
  • Surgical patients
  • Serious diseases and infection
  • Alcoholic pancreatitis
  • Hypertriglyceridemia pancreatitis
  • Disorder of Glucolipide Metabolism:diabetes mellitus, hypertriglyceridemia, BMI>30

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
mortalityup to 28 days

The level of serum maresin-1 predicts the severity of severe acute pancreatitis

Secondary Outcome Measures
NameTimeMethod
The incidence of MODSthrough study completion, an average of 1 year

The level of serum maresin-1 predicts the severity of severe acute pancreatitis

The incidence of IPNthrough study completion, an average of 1 year

The level of serum maresin-1 predicts the severity of severe acute pancreatitis

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.